CYTX received US Patent No. 7,771,716 (“716” patent) for Celution® System based methods Read more…
KOOL’s Board of Directors has unanimously approved a reverse split of its common stock at a ratio of 1 new share for each 4 existing shares effective on 8/26/10.
NBS has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, Read more…
Q2/10 net loss was $2.9 M or $0.00 per share on fully diluted shares of 884 M shares; with the 1st half of FY10 net loss was $15 M or $0.02 on fully diluted shares of 708.5 M shares. Read more…
The FDA is seeking to stop a Colorado company from offering an autologous stem cell therapy for arthritic knees and other orthopedic problems Read more…
STEM reported net loss of $4.61 M, or $0.04 per share. Read more…
Tissue Regenix received EU CE Marking for its dCELL vascular patch. Read more…
A revolutionary technique that could allow damaged hearts to repair themselves has been devised. Read more…
UCSF researchers are reporting the 1st success in rapidly purifying 1 type of embryonic stem cell from a mix of many different types of embryonic stem cells Read more…
Net loss for Q/2/10 was $3.1M or $0.16 per share. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.